Burden of Crohn's disease: Economics and quality of life aspects in Italy

ClinicoEconomics and Outcomes Research

Volumn 4, Issue 1, 2012, Pages 209-218

  Benedini, Viviano ^a   Caporaso, Nicola ^b   Corazza, Gino Roberto ^c   Rossi, Zaccaria ^d   Fornaciari, Giovanni ^a   Cottone, Mario ^e   Frosini, Giorgio ^f   Caruggi, Mauro ^g   Ottolini, Chiara ^g   Colombo, Giorgio L ^h,i  

^a Department of Gastroenterology AO Carlo Poma ^*  (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d REGINA APOSTOLORUM HOSPITAL   (Italy)

^e VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^f UNIVERSITY HOSPITAL OF SIENA   (Italy)

^g Azienda Ospedaliera S Antonio Abate di Gallarate   (Italy)

^h UNIVERSITY OF PAVIA   (Italy)

ⁱ SAVE Studi Analisi Valutazioni Economiche   (Italy)

Author keywords

Cost analysis; Cost of illness; Crohn's disease; Economic evaluation; EQ5D; EuroQol; Quality of life

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; CROHN DISEASE; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH SERVICE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SEX DIFFERENCE;

EID: 84930476821     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S31114     Document Type: Article

References (36)

1. Achkar JP, Barmada MM, Duerr RH. Perinuclear neutrophil antibodies are not markers for genetic susceptibility or indicators of genetic heterogeneity in familial ulcerative colitis. Am J Gastroenterol. 2002;97: 2343-2349.
2. Lashner BA. Colorectal cancer surveillance for patients with inflammatory bowel disease. Gastrointest Endosc Clin N Am. 2002;12: 135-143.
3. Wolf JM, Lashner BA. Inflammatory bowel disease: sorting out the options. Cleve Clinic J Med. 2002;69:621-631.
4. Mattar MC, Lough D, Pishvaian MJ, Charabaty A. Current management of inflammatory bowel disease and colorectal cancer. Gastrointest Cancer Res. 2011;4:53-61.
5. Peura D, Fennerty B, Lashner B. Osteoporosis for the Gastroenterologist. Hertfordshire, UK: Strategic Consultants International; 2002.
6. Lucioni C. La qualità della vita nella valutazione economica. Cronache Farmaceutiche, Anno XXXVII, N. 6, 1994. Italian.
7. Hodgson T. The state of the art of cost of illness estimates. Adv Health Econ Health Serv Res. 1983;4:129-164.
8. Drummond MF, O'Brien BJ, Stoddart GL, et al. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. New York, NY: Oxford University Press; 2006.
9. Blomqvist P, Ekbom A. Inflammatory bowel diseases: health care and costs in Sweden in 1994. Scand J Gastroenterol. 1997;32: 1134-1139.
10. Bernstein CN, Papineau N, Zajaczkowki J, et al. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Am J Gastroenterol. 2000;95:677-683.
11. Cohen RD, Larson LR, Roth JM, Becker RV, Mummert LL. The cost of hospitalization in Crohn's disease. Am J Gastroenterol. 2000;95: 524-530.
12. Silverstein D, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Chron's disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999;117:49-57.
13. Feagan BG. Review article: economic issues in Crohn's disease-assessing the effects of new treatments on health-related quality of life. Aliment Pharmacol Ther. 1999;13 Suppl 4:29-37.
14. Borgaonkar MR, Irvine JR. Quality of life measurement in gastrointestinal and liver disorders. Gut. 2000;47:444-454.
15. Lichtenstein GR, Bala M, Han C, DeWoody K, Schaible T. Infliximab improves quality of life in patients with Crohn's disease. Inflamm Bowel Dis. 2002;8:237-243.
16. Italian Health Economics Association. Guidelines proposal on how to conduct economic evaluation studies of health programs. Pharmacoeconomics-Italian Research Articles. 2009;11:83-93. Italian.
17. Health Ministry, DRG Tariff. TUC Tariffa Unica Convenzionale, Conferenza delle Regioni e delle Province Autonome, compensazione interregionale della mobilità sanitaria Testo Unico, Versione in vigore per le attività dell'anno 2010. Rome, May 5, 2011. Italian.
18. Health Ministry. 2010 National Tariff Nomenclator. Nomenclatore delle Prestazioni di assistenza specialistica ambulatoriale, Ministero della Salute, 2011. Italian.
19. Italian Medicines Agency. Negoziazione e rimborsabilità. Italian. Available from: http://www.agenziafarmaco.gov.it/it/content/negoziazione-e-rimborsabilit%C3%A0. Accessed September 23, 2011.
20. Banca d'Italia. La ricchezza delle famiglie italiane-anno 2010, n. 64-2011 14-12-2011. Italian. Available from: http://www.bancaditalia.it/statistiche/stat_mon_cred_fin. Accessed April 21, 2012.
21. ISTAT Istituto Nazionale di Statistica. Nation Institute of Statistics. Italian. Available from: http://seriestoriche.istat.it/index.php?id=7&user_100ind_pi1[id_pagina]=70&cHash=468e508f3b1982a1c919b740b8f13d66. Accessed April 21, 2012.
22. EQ-5D™ [homepage on the Internet]. Rotterdam, The Netherlands: EuroQol Group. Available from: http://www.euroqol.org. Accessed April 21, 2012.
23. [No authors listed]. EuroQoL: a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199-208.
24. Essink-Bot ML, Stouthard ME, Bonsel GJ. Generalizability of valuations on health states collected with the EuroQolc-questionnaire. Health Econ. 1993;2:237-246.
25. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37: 53-72.
26. Kind P. The EuroQol instrument: an index of health-related quality of life. In: Spiker B, editor. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. Philadelphia, PA: Lippincott-Raven Publishers; 1996.
27. Dolan P, Gudex C, Kind P, et al. A Social Tariff for EuroQol: Results from a UK General Population Survey, Discussion Paper 138. New York, NY: Centre of Health Economics, University of York; 1995.
28. Feagan BG, Vreeland MG, Larson LR, et al. Annual cost of care for Crohn's disease: a payor prospective. Am J Gastroenterol. 2000;95: 1955-1960.
29. Lucioni C, Garancini MP, Massi-Benedetti M, Mazzi S, Serra G. The costs of type 2 diabetes mellitus in Italy: a CODE-2sub-study. Treat Endocrinol. 2003;2:121-133.
30. Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther. 2009;30:265-274.
31. Dretzke J, Edlin R, Round J, et al. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease. Health Technol Assess. 2011;15:1-244.
32. Binion DG, Louis E, Oldenburg B, et al. Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn's disease: a meta-analysis. Can J Gastroenterol. 2011;25:492-496.
33. Yu AP, Johnson S, Wang ST, et al. Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease. Pharmacoeconomics. 2009;27:609-621.
34. Loomes DE, Teshima C, Jacobs P, Fedorak RN. Health care resource use and costs in Crohn's disease before and after infliximab therapy. Can J Gastroenterol. 2011;25:497-502.
35. Sprakes MB, Ford AC, Suares NC, et al. Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience. Aliment Pharmacol Ther. 2010;32:1357-1363.
36. Koopmanshap MA. Cost of illness studies: useful for health policy? Pharmacoeconomics. 1998;14:143-148.